LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Signals from Neighboring Dendritic Cells Drive Leukemia Growth

By LabMedica International staff writers
Posted on 22 Feb 2016
Image: T-cell acute lymphoblastic leukemia (T-ALL), a cancer that strikes primarily in childhood, can only survive and grow when sent a signal from neighboring cells called dendritic cells (shown in green) in the tumor\'s near environment (Photo courtesy of the University of Texas, Austin).
Image: T-cell acute lymphoblastic leukemia (T-ALL), a cancer that strikes primarily in childhood, can only survive and grow when sent a signal from neighboring cells called dendritic cells (shown in green) in the tumor\'s near environment (Photo courtesy of the University of Texas, Austin).
Noncancerous cells in the immediate tumor microenvironment supply signals that drive T-cell acute lymphoblastic leukemia (T-ALL) growth, and may become attractive therapeutic targets to control the disease.

T-ALL cells require signals derived from noncancerous cells to survive. Although many studies have identified alterations in signaling pathways that promote T-ALL growth, the identity of endogenous stromal cells and their associated signals in the tumor microenvironment that support T-ALL remains unknown.

In order to identify the cells that provide growth signals to T-ALL, investigators at the University of Texas (Austin, USA) examined the thymic tumor microenvironments in multiple murine T-ALL models and in human patient samples.

They reported in the February 9, 2016, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that systematic evaluation of the functional capacity of tumor-associated stromal cells revealed that myeloid cells, primarily dendritic cells (DCs), were necessary and sufficient to support T-ALL survival. DCs supported T-ALL growth both in primary thymic tumors and at secondary tumor sites.

To identify a molecular mechanism by which DCs supported T-ALL growth, the investigators performed gene expression (transcriptome) profiling. Results of these studies revealed up-regulation of platelet-derived growth factor receptor beta (Pdgfrb) and insulin-like growth factor I receptor (Igf1r) on T-ALL cells, with concomitant expression of their ligands by tumor-associated DCs. Both Pdgfrb and Igf1r were activated in T-ALL cell cultures. Co-culture with tumor-associated, but not normal thymic DCs, sustained IGF1R activation. Furthermore, IGF1R signaling was necessary for DC-mediated T-ALL survival.

"It is only more recently that people have really appreciated that tumors are complex organs in and of themselves with all of the heterogenous cell types that can talk to each other and promote each other's survival and proliferation," said senior author Dr. Lauren Ehrlich, assistant professor of molecular biosciences at the University of Texas.

The current paper provides the first evidence that endogenous tumor-associated DCs supply signals driving T-ALL growth, and implicate tumor-associated DCs and their mitogenic signals as attractive therapeutic targets. "If we can find directed therapies to more specifically target the tumors without being overly toxic to the person, that would obviously be much better," said Dr. Ehrlich.

Related Links:

University of Texas


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more